Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EX16
|
| gptkbp:CASNumber |
1108743-60-7
|
| gptkbp:chemicalFormula |
C31H34F2N6O2
|
| gptkbp:developer |
gptkb:Genentech
gptkb:Roche |
| gptkbp:genericName |
gptkb:entrectinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rozlytrek
|
| gptkbp:indication |
metastatic non-small cell lung cancer
solid tumors with NTRK gene fusion |
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea constipation dizziness fatigue weight gain cognitive disorders |
| gptkbp:target |
gptkb:TRK
gptkb:ALK ROS1 |
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
solid tumors with NTRK gene fusion |
| gptkbp:bfsParent |
gptkb:Roche
|
| gptkbp:bfsLayer |
6
|